Healthmatters: A Continuing Medical Education Company 

   |  About HealthmattersCME  |  CME Council  |  Contact

« Back to Psychiatry/Neurology

Individualizing Evidence-Based MAT for Opioid-Use Disorder: Improving Patient Outcomes Through Adherence to Therapy

: Internet Activity
: 1.0 AMA PRA Category 1 Credits™
Target Audience
: Physicians, PAs, Nurse practitioners
Expiration Date
: 03/23/2016

Read the content below to launch the activity

Release Date: March 23, 2015
Expiration Date: March 23, 2016
Activity Description
In 2012, an estimated 6.75 million Americans aged 12 years and older were current, nonmedical, psychotherapeutic-drug users. An estimated 75% of these agents were opioid analgesic medications, second in prevalence only to marijuana use.1 Opioid-usedisorder (OUD) has been reported to affect almost 1% of the US population, making it a source of nationwide attention.1-3 Among patients receiving legitimate prescriptions for chronic pain, the percentage developing OUD has been reported to vary widely in different studies.4 Because disabling chronic pain affects roughly 75 million Americans for an annual cost of $100 billion, the potential burden of OUD on the health care system is high.5,6 Psychiatrists and other mental health care professionals must be able to apply current evidence-based best practices to the management of their patients with OUD to improve long-term outcomes and prevention of relapse.
During this video roundtable, the faculty will use patient-case presentations to assist participants with optimizing their management strategies for patients with OUD. This activity will present the practical considerations of discussing the disorder with patients, assessing their readiness for behavioral change, developing medication-assisted-treatment (MAT) plans that integrate both psychosocial and pharmacotherapeutic approaches, assisting patients in maintaining abstinence and preventing relapse, and motivating them to successfully change their lifestyle.
1. US Department of Health and Human Services. SAMHSA. Center for Behavioral Health Statistics and Quality. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD; 2012. 
2. National Center on Addiction and Substance Abuse (CASA). Addiction Medicine: Closing the Gap between Science and Practice. New York, NY: Columbia University; 2012. 
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013. 
4. Fishbain DA, Cole B, Lewis J, et al. Pain Med. 2008;9:444-459. 
5. McCarberg BH, Nicholson BD, Todd KH, et al. Am J Therapeutics. 2008;15:312-320. 
6. American Pain Foundation. Pain Facts and Stats. 2008. PainFactsandStats.pdf. Accessed November 5, 2014.
Learning Objectives
After completing this activity, participants should be better able to:
  • Describe the neurobiology underlying the brain reward system and its clinical implications for diagnosing substance-usedisorders
  • Review factors that facilitate or hinder adherence to OUD treatment and assess patient readiness for changing behavior related to opioid analgesic use
  • Compare the mechanism of action, efficacy, and safety of the different FDA-approved pharmacotherapies for the treatment of OUD
  • Evaluate evidence-based, treatment-matching strategies for OUD and approaches to overcoming barriers to treatment adherence
Target Audience
This activity has been designed to meet the educational needs of psychiatrists, psychologists, and other allied mental health care providers interested in improving their care of patients with opioid-use disorder.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and HealthmattersCME. Global is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please contact Global at 303-395-1782
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient-care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Charles P. O'Brien, MD, PhD                
Grant/Research Support: Alkermes; AstraZeneca; Embera NeuroTherapeutics, Inc; Tekmira Pharmaceuticals
Jennifer S. Potter, PhD, MPH               
Grant/Research Support: NIH-NIDA (institutional grant)
Honoraria: California Society of Addiction Medicine
Roger D. Weiss, MD                             
Consultant/Independent Contractor: Reckitt Benckiser Scientific Advisory Board
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Andrea Funk                                          Nothing to disclose
Amanda Glazar, PhD                              Nothing to disclose
Ashley Marostica, RN, MSN                   Nothing to disclose
James Murphy                                        Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and HealthmattersCME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must review the content, complete the post-test, with a passing score of 70% or higher, and complete the evaluation form.
This activity is jointly provided by Global Education Group and HealthmattersCME.
Statement of Commercial Support
This activity is supported by an independent educational grant from Alkermes.

Stay Informed

Please click here to register if you would like to be added to our mailing list to receive information on educational materials.

Sign Up Now



Stay Informed

Close this box
required required
Invalid Email required
required required
Submit Close